Navigation Links
Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
Date:2/7/2013

Basel (Switzerland) and Tokyo (Japan) (PRWEB) February 07, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Ono Pharmaceutical Co., Ltd.. (Ono) extended its Genedata collaboration with a license of Genedata Expressionist for Mass Spectrometry. Ono is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by Ono to further strengthen its targeted proteomics and metabolomics research.

“Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis,” noted a spokesperson for the Tsukuba Research Institute at Ono. “Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB. And, the system’s ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes.”

Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomics, proteomics, metabolomics, and epigenomics data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomics, and lipidomics data from all major MS technologies. With robust support of MRM data, the system’s innovative capabilities include:

  •     Data Visualization
  •     Background Subtraction
  •     Grid Alignment
  •     Peak Detection
  •     Annotation

“We are proud of our collaboration with Ono, one of the world’s leading pharmaceutical companies providing innovative drug therapies,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as Ono who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10357457.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Packaging Machinery Manufacturer, Sepha Ltd.Reports Record Year for Sales of its Visionscan Leak Detection Machine and its Pharmaceutical Deblistering Equipment
2. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
3. Oramed Pharmaceuticals Announces Reverse Stock Split
4. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
7. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
8. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
9. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @ RnRMarketResearch.com
10. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
11. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):